Columbus Circle Investors lowered its holdings in shares of Illumina (NASDAQ:ILMN) by 6.2% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 97,963 shares of the life sciences company’s stock after selling 6,496 shares during the period. Columbus Circle Investors’ holdings in Illumina were worth $23,160,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. Financial Gravity Companies Inc. acquired a new stake in shares of Illumina during the fourth quarter worth $106,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of Illumina during the first quarter worth $113,000. SeaCrest Wealth Management LLC acquired a new stake in shares of Illumina during the fourth quarter worth $154,000. Captrust Financial Advisors acquired a new stake in shares of Illumina during the fourth quarter worth $165,000. Finally, Mitsubishi UFJ Securities Holdings Co. Ltd. increased its position in shares of Illumina by 113.9% during the fourth quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 770 shares of the life sciences company’s stock worth $168,000 after buying an additional 410 shares during the period. 91.59% of the stock is owned by hedge funds and other institutional investors.
Get Illumina alerts:
Several equities research analysts have recently weighed in on ILMN shares. Cowen increased their price objective on shares of Illumina from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Monday, January 22nd. First Analysis upgraded shares of Illumina from an “equal weight” rating to an “overweight” rating and set a $277.00 price objective for the company in a research report on Wednesday, January 31st. Canaccord Genuity reiterated a “buy” rating and set a $265.00 price objective (up from $255.00) on shares of Illumina in a research report on Wednesday, January 31st. Leerink Swann increased their price objective on shares of Illumina from $250.00 to $276.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. Finally, Morgan Stanley increased their price objective on shares of Illumina from $145.00 to $157.00 and gave the stock an “underweight” rating in a research report on Wednesday, January 31st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $251.14.
In other news, CEO Francis A. Desouza sold 2,100 shares of Illumina stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $268.63, for a total transaction of $564,123.00. Following the completion of the transaction, the chief executive officer now directly owns 87,371 shares in the company, valued at $23,470,471.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert S. Epstein sold 250 shares of Illumina stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $231.25, for a total transaction of $57,812.50. Following the transaction, the director now owns 7,088 shares of the company’s stock, valued at $1,639,100. The disclosure for this sale can be found here. Insiders sold 16,614 shares of company stock valued at $4,018,424 over the last 90 days. Corporate insiders own 0.54% of the company’s stock.
NASDAQ:ILMN opened at $268.45 on Friday. The company has a quick ratio of 2.41, a current ratio of 2.71 and a debt-to-equity ratio of 0.23. The firm has a market capitalization of $38.77 billion, a price-to-earnings ratio of 67.11, a P/E/G ratio of 2.71 and a beta of 0.86. Illumina has a 12 month low of $264.12 and a 12 month high of $267.94.
Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, April 24th. The life sciences company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.02 by $0.43. The business had revenue of $782.00 million during the quarter, compared to analysts’ expectations of $744.30 million. Illumina had a net margin of 19.31% and a return on equity of 24.93%. The business’s quarterly revenue was up 30.8% on a year-over-year basis. During the same period last year, the company posted $0.64 earnings per share. research analysts anticipate that Illumina will post 4.87 EPS for the current year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina (NASDAQ:ILMN).